Discovery is just the first step on the journey to an approved therapeutic and at PetMedix we are taking our assets all the way.
In these modern times, it is comparatively easy to raise an antibody against a target. However, it remains very challenging to discover and develop one with the combination of properties required to not only achieve regulatory approval, but to also become a commercial success. Our clinical development team, lead by Dr Dave Lowery, has the experience and know-how required to take an antibody sequence and turn it into an approved medicine. Once a suitable candidate is identified the clinical development team advances it, using a mix of internal and partnered resources, through all of the manufacturing and clinical milestones on the route to approval.
What sets us apart at PetMedix are the teams we have built and what they are able to achieve.
Click through below to learn more about each of our six core groups: